Enliven Therapeutics director sells 13,000 shares

Q: How many ELVN shares did director J. Scott Garland exercise and sell, and at what prices?

J. Scott Garland exercised options covering 13,000 shares at an exercise price of $15.47 per share on October 1, 2026, acquired 13,000 common shares, and sold 13,000 shares at a weighted average price of $46.6707 per share. The reported sale prices ranged from $46.62 to $46.87 per share.

Q: What were the vesting terms for J. Scott Garland's ELVN option?

The option was originally for 59,372 shares and vests as to 1/36th of the shares on February 7, 2026, and each month thereafter, subject to J. Scott Garland continuing as an outside director through each such date.

The option position was 46,372 shares after the exercise, and vesting required J. Scott Garland to remain an outside director through each vesting date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Director J. Scott Garland exercised options covering 13,000 ELVN shares on October 1, 2026, at an exercise price of $15.47 per share, acquired 13,000 common shares, and sold 13,000 shares at a weighted average $46.6707 per share. The reported sale prices ranged from $46.62 to $46.87 per share. The reported option position was 46,372 shares following the exercise. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and Sale: 13,000 shares ($406K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Garland J. Scott

Role Director

Sold 13,000 shs ($607K)

Approx. gross sale proceeds $607K

Approx. exercise cost $201K

Approx. pre-tax spread $406K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^F2	13,000	$0.00	$0.00
Exercise	Common Stock	13,000	$15.47	$201K
Sale	Common Stock ^F1	13,000	$46.6707	$607K

Holdings After Transaction: Stock Option (right to buy) — 46,372 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

F1. This transaction was executed in multiple trades at prices ranging from $46.62 to $46.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F2. The option, originally for 59,372 shares, vests as to 1/36th of the shares on February 7, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

Key Figures

Options exercised: 13,000 shares Exercise price: $15.47 per share Common shares acquired: 13,000 shares +4 more

7 metrics

Options exercised 13,000 shares October 1, 2026

Exercise price $15.47 per share Options exercised October 1, 2026

Common shares acquired 13,000 shares October 1, 2026

Shares sold 13,000 shares October 1, 2026

Weighted average sale price $46.6707 per share October 1, 2026

Reported sale-price range $46.62 to $46.87 per share October 1, 2026

Option position following exercise 46,372 shares Following the October 1, 2026 exercise

Key Terms

Stock Option (right to buy), weighted average sale price, vests as to 1/36th

3 terms

Stock Option (right to buy) technical

"Stock Option (right to buy)"

weighted average sale price financial

"price reported above reflects the weighted average sale price"

vests as to 1/36th financial

"vests as to 1/36th of the shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ELVN shares did director J. Scott Garland exercise and sell, and at what prices?

J. Scott Garland exercised options covering 13,000 shares at an exercise price of $15.47 per share on October 1, 2026, acquired 13,000 common shares, and sold 13,000 shares at a weighted average price of $46.6707 per share. The reported sale prices ranged from $46.62 to $46.87 per share.

What were the vesting terms for J. Scott Garland's ELVN option?

The option was originally for 59,372 shares and vests as to 1/36th of the shares on February 7, 2026, and each month thereafter, subject to J. Scott Garland continuing as an outside director through each such date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/05/2026 - 04:57 PM Accepted by SEC EDGAR 10/05/2026 - 04:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garland J. Scott

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME

CALIFORNIA

94010

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M		13,000	A	$15.47	13,000	D
Common Stock	10/01/2026		S		13,000	D	$46.6707⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$15.47	10/01/2026		M			13,000	⁽²⁾	01/07/2036	Common Stock	13,000	$0	46,372	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $46.62 to $46.87. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

2. The option, originally for 59,372 shares, vests as to 1/36th of the shares on February 7, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

	/s/ Ben Hohl, by power of attorney	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR